ALVO
Alvotech
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IS
$5.32
−1.12%Year over year
Reported trailing growth
- Revenue
- -12.2%
- EBITDA
- —
- EBIT
- -13.7%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +49.4%
- EBITDA
- —
- EPS
- +125.3%
Three-year CAGR
- Revenue
- +91.9%
- EBITDA
- +1102.0%
- EBIT
- +12.3%
- Net income
- +112.0%
- EPS
- +111.5%
- Free cash flow
- +61.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026